Pancreatic Cancer Research

ResearcherUniversity of Tennessee Health Science CenterActive in the last 2 years

Wěi Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9522-4474; OpenAlex author ID A5100318325. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 18

  1. Anti-mitotic agent SB-216 overcomes taxane resistance in castration-resistant prostate cancer and exhibits anti-tumour efficacy in pancreatic cancer. Last author DOI 10.1111/bph.70294↗
  2. Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death. Co-author DOI 10.1016/j.jpet.2025.103751↗
  3. Prognostic evaluation of pancreatic cancer based on the model of chemo-radiotherapy resistance-related genes. Co-author DOI 10.21037/jgo-23-308↗
  4. High‑glucose microenvironment promotes perineural invasion of pancreatic cancer via activation of hypoxia inducible factor 1α. Co-author DOI 10.3892/or.2022.8275↗
  5. Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2020.09.052↗
  6. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑κB axis. Co-author DOI 10.3892/or.2020.7600↗
  7. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Co-author DOI 10.1186/s13046-018-1009-7↗
  8. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  9. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways. Co-author DOI 10.3892/or.2018.6833↗
  10. MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior. Co-author DOI 10.7150/ijbs.22555↗
  11. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Co-author DOI 10.3892/ijo.2016.3779↗
  12. Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. Co-author DOI 10.1186/s13045-016-0237-6↗
  13. Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. Co-author DOI 10.3892/or.2015.4504↗
  14. Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Last author DOI 10.3892/or.2016.4709↗
  15. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Co-author DOI 10.1007/s10620-015-3759-9↗
  16. Superoxide dismutase promotes the epithelial-mesenchymal transition of pancreatic cancer cells via activation of the H2O2/ERK/NF-κB axis. Co-author DOI 10.3892/ijo.2015.2938↗
  17. [Down-regulated expression of PP2A catalytic subunit in pancreatic cancer cells promotes cell growth]. Co-author PMID 24721345↗
  18. Aspirin: a potential therapeutic approach in pancreatic cancer. Co-author DOI 10.2174/09298673113209990196↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 7 shared papers, 2013–2020 · strength 0.57
  2. Chun Cai · 2 shared papers, 2025–2026 · strength 0.53
  3. Evan Scott Glazer · 2 shared papers, 2025–2026 · strength 0.53
  4. Jianjun Lei · 4 shared papers, 2016–2020 · strength 0.37
  5. Lei Cao · 4 shared papers, 2015–2019 · strength 0.32
  6. Rui Wang · 1 shared paper, 2026 · strength 0.29
  7. Michael W. Spinrad · 1 shared paper, 2025 · strength 0.24
  8. Zheng Wang · 2 shared papers, 2019–2020 · strength 0.22
  9. Hui‐Chuan Sun · 1 shared paper, 2023 · strength 0.20
  10. Kai Chen · 1 shared paper, 2023 · strength 0.20
  11. Lun Zhang · 2 shared papers, 2013–2022 · strength 0.19
  12. Qinhong Xu · 3 shared papers, 2013–2019 · strength 0.19
  13. Weili Min · 1 shared paper, 2022 · strength 0.16
  14. Xin Zhang · 1 shared paper, 2022 · strength 0.16
  15. Wunai Zhang · 1 shared paper, 2022 · strength 0.16
  16. Wanxing Duan · 2 shared papers, 2016–2019 · strength 0.16
  17. Tao Shan · 2 shared papers, 2017–2018 · strength 0.16
  18. Ya’an Kang · 2 shared papers, 2017–2018 · strength 0.16
  19. Zheng Wu · 1 shared paper, 2020 · strength 0.13
  20. Liankang Sun · 1 shared paper, 2020 · strength 0.13
  21. Virender Kumar · 1 shared paper, 2021 · strength 0.13
  22. Rajan Sharma Bhattarai · 1 shared paper, 2021 · strength 0.13
  23. Tatiana K. Bronich · 1 shared paper, 2021 · strength 0.13
  24. Ram I. Mahato · 1 shared paper, 2021 · strength 0.13
  25. Liang Han · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.